Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

This is a long-term follow-up (LTFU) study for people who previously received NTLA-2001, an investigational CRISPR-based gene-editing therapy developed by Intellia Therapeutics. NTLA-2001 is being studied as a treatment for transthyretin amyloidosis (ATTR), a progressive disease where misfolded protein builds up in organs, particularly the heart and nerves. This follow-up study monitors participants for years after dosing to track long-term safety and durability of the gene editing. You may be eligible if: - You previously participated in an Intellia-sponsored clinical trial and received a full or partial dose of NTLA-2001 - You are willing to provide informed consent for this long-term follow-up study You may NOT be eligible if: - There are no exclusion criteria listed for this study — eligibility is determined solely by prior participation in the NTLA-2001 trial Talk to your doctor to see if this trial is right for you.